- Home
- Publications
- Publication Search
- Publication Details
Title
The future of antiviral immunotoxins
Authors
Keywords
-
Journal
JOURNAL OF LEUKOCYTE BIOLOGY
Volume 99, Issue 6, Pages 911-925
Publisher
Wiley
Online
2016-01-05
DOI
10.1189/jlb.2mr1015-468r
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of denileukin diftitox (Dd) in cutaneous T-cell lymphoma (CTCL) patients: Integrated analysis of three large phase III trials
- (2017) A. Negro-Vilar et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies.
- (2017) A. Dean et al. JOURNAL OF CLINICAL ONCOLOGY
- Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo
- (2015) Katja Spiess et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Unexpected patterns of Epstein–Barr virus transcription revealed by a High throughput PCR array for absolute quantification of viral mRNA
- (2015) Rosemary J Tierney et al. VIROLOGY
- Broad-spectrum antiviral agents
- (2015) Jun-Da Zhu et al. Frontiers in Microbiology
- The Viral G Protein-Coupled Receptor ORF74 Hijacks β-Arrestins for Endocytic Trafficking in Response to Human Chemokines
- (2015) Sabrina M. de Munnik et al. PLoS One
- Antiviral Activity of a Single-Domain Antibody Immunotoxin Binding to Glycoprotein D of Herpes Simplex Virus 2
- (2014) Eileen M. Geoghegan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive, Locally Advanced, or Metastatic Breast Cancer
- (2014) Kathy D. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification and Functional Comparison of Seven-Transmembrane G-Protein-Coupled BILF1 Receptors in Recently Discovered Nonhuman Primate Lymphocryptoviruses
- (2014) Katja Spiess et al. JOURNAL OF VIROLOGY
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- (2014) Ian E Krop et al. LANCET ONCOLOGY
- The development of immunoconjugates for targeted cancer therapy
- (2014) Brandon G. Smaglo et al. Nature Reviews Clinical Oncology
- Herpesvirus-encoded GPCRs: neglected players in inflammatory and proliferative diseases?
- (2014) Henry F. Vischer et al. NATURE REVIEWS DRUG DISCOVERY
- Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes
- (2014) R. Mazor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART
- (2014) Paul W. Denton et al. PLoS Pathogens
- Thirty Years of HIV and AIDS: Future Challenges and Opportunities
- (2013) Carl W. Dieffenbach et al. ANNALS OF INTERNAL MEDICINE
- Thirty years on: HIV receptor gymnastics and the prevention of infection
- (2013) Robin A Weiss BMC BIOLOGY
- Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer
- (2013) Manfred Welslau et al. CANCER
- Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2013) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
- (2013) R. Hassan et al. Science Translational Medicine
- B cell localization: regulation by EBI2 and its oxysterol ligand
- (2013) Dominique Gatto et al. TRENDS IN IMMUNOLOGY
- Immunotoxins: The Role of the Toxin
- (2013) Antonella Antignani et al. Toxins
- Risks and untoward toxicities of antibody-based immunoconjugates
- (2012) Dana Litvak-Greenfeld et al. ADVANCED DRUG DELIVERY REVIEWS
- Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies
- (2012) G. Borthakur et al. HAEMATOLOGICA
- A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
- (2012) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
- (2012) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein
- (2012) Deboeeta Chatterjee et al. mAbs
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pre-Clinical Evaluation of a 213Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication
- (2012) Ekaterina Dadachova et al. PLoS One
- Prevention of Cellular Suicide by Cytomegaloviruses
- (2012) Patricia M. Fliss et al. Viruses-Basel
- An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection
- (2011) Yingyun Cai et al. ANTIVIRAL RESEARCH
- A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
- (2011) M. A. Fanale et al. CLINICAL CANCER RESEARCH
- Therapeutic potential of anticancer immunotoxins
- (2011) Swati Choudhary et al. DRUG DISCOVERY TODAY
- A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer
- (2011) John E. Weldon et al. FEBS Journal
- HSV-2: in pursuit of a vaccine
- (2011) Christine Johnston et al. JOURNAL OF CLINICAL INVESTIGATION
- A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254
- (2011) Richard R. Furman et al. LEUKEMIA & LYMPHOMA
- Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
- (2010) A. S. Wayne et al. CLINICAL CANCER RESEARCH
- Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma
- (2010) H. Miles Prince et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiretroviral therapy and management of HIV infection
- (2010) Paul A Volberding et al. LANCET
- Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
- (2010) S. Kunwar et al. NEURO-ONCOLOGY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cell transformation mediated by the Epstein–Barr virus G protein-coupled receptor BILF1 is dependent on constitutive signaling
- (2010) R Lyngaa et al. ONCOGENE
- Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs
- (2010) Edward A. Berger et al. PLoS Pathogens
- Radioimmunotherapy of Solid Tumors: Searching for the Right Target
- (2010) Hong Song et al. Current Drug Delivery
- A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
- (2009) Andres Forero-Torres et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
- (2009) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- Anti-CD3 Recombinant Diphtheria Immunotoxin Therapy of Cutaneous T Cell Lymphoma
- (2009) A. Frankel et al. CURRENT DRUG TARGETS
- Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia
- (2009) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- A novel composite immunotoxin that suppresses rabies virus production by the infected cells
- (2009) Tatiana Mareeva et al. JOURNAL OF IMMUNOLOGICAL METHODS
- An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection
- (2008) Katharine Looker BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Targeted therapy of cancer using diphtheria toxin-derived immunotoxins
- (2008) Sirisha Potala et al. DRUG DISCOVERY TODAY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now